Alliance Global Partners Sticks to Their Buy Rating for Reviva Pharmaceuticals Holdings (RVPH)

Tip Ranks
2025.11.17 16:55
portai
I'm PortAI, I can summarize articles.

Alliance Global Partners analyst James Molloy reiterated a Buy rating for Reviva Pharmaceuticals Holdings, setting a price target of $16.00. Molloy, who covers the Healthcare sector, has an average return of -26.0% and a 23.12% success rate on recommended stocks. Reviva Pharmaceuticals Holdings has a consensus Strong Buy rating with a price target of $5.14.

Alliance Global Partners analyst James Molloy reiterated a Buy rating on Reviva Pharmaceuticals Holdings on November 14 and set a price target of $16.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Molloy covers the Healthcare sector, focusing on stocks such as Pelthos Therapeutics, Talphera, and Imunon. According to TipRanks, Molloy has an average return of -26.0% and a 23.12% success rate on recommended stocks.

Reviva Pharmaceuticals Holdings has an analyst consensus of Strong Buy, with a price target consensus of $5.14.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.